NL-OMON36800已完成不适用
A double-blind, randomised, placebo-controlled, combined single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetic, including food interaction, and pharmacodynamic profile of BIA 5-1058, in healthy male volunteers. - BIA 5-1058 SAD/MAD study.
Bial Portela & Ca.0 个研究点目标入组 108 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male, 18 - 55 years, BMI 18.0 - 30.0 kg/m2.
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A double-blind, randomized, placebo-controlled, combined single and multiple ascending dose study to investigate the safety, tolerability and pharmacokinetic profile of AB928 in healthy volunteers.NL-OMON46373Arcus Biosciences, Inc.86
招募中
不适用
STUDY to understand the effect and tolerance of Experimental product in patient with UPPER RESPIRATORY TRACT INFECTIONS (URTI)CTRI/2021/09/036807Vedic Lifesciences Pvt Ltd
已完成
2 期
Effects of concomitant treatment with an androgen on androgen metabolism, biochemical parameters, mood, fat, muscle and bone in women using an oral contraceptioISRCTN06414473Pantarhei Bioscience BV (Netherlands)100
进行中（未招募）
1 期
A double-blind, placebo controlled, randomised, comparative 2-way crossover study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on sexual arousability and the vascular component of the sexual arousal response during self-induced erotic fantasy and visual sexual stimulation in women using oral contraception (150 mcg levonorgestrel and 30 mcg ethinylestradiol or 3 mg drospirenone and 30 mcg ethinylestradiol) - ARC studyEUCTR2007-000013-10-NLPantarhei Bioscience B.V.82
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) plus placebo to mobilize and collect greater than or equal to 6x10e6 CD34+ cells/kg in multiple myeloma patients for autologous transplantation - N/AEUCTR2005-003599-39-DEAnorMED Corp.10